Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw

doi:10.12337/zgkqjxjyzz.2025.05.001

Chinese Journal of Stomatological Continuing Education ›› 2025, Vol. 28 ›› Issue (5): 297-306.DOI: 10.12337/zgkqjxjyzz.2025.05.001

Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw

Yihui Ding¹, Dandan Wang², Chenlu Li², Jihong Wang², Lei Tian^2,*, Chunlin Zong^2,*

¹Sixteenth Team, Fourth Cadet Regiment, Air Force Medical University, Xi’an, Shaanxi Province, P.R. China;
²State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases & Shaanxi Clinical Research Center for Oral Diseases & Department of Oral and Maxillofacial Surgery, School of Stomatology, The Third Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province, P.R. China

Online:2025-09-30 Published:2025-09-30
Contact: Chunlin Zong, Lei Tian. Tel: 029-84776109. Emails: mujiezi23@163.com; tianleison@163.com. Address: No. 145 Changle West Road, Xincheng District, Xi’an 710032, Shaanxi Province, P.R. China.

Abstract

Abstract: Medication related osteonecrosis of the jaw (MRONJ) is a serious complication that occurs after the use of anti bone resorption, anti angiogenesis, and other drugs.In recent years, scholars have found that Teriparate has therapeutic effects on MRONJ. This article elaborates on the diagnostic criteria and staging of MRONJ through literature review, summarizes the therapeutic effects, administration methods, combination therapy, and possible treatment mechanisms of Teriparate for MRONJ, and provides a basis and reference for the clinical application and scientific research of Teriparate in the treatment of MRONJ.

Key words: medication-related osteonecrosis of the jaw, teriparatide, conservative treatment, drug therapy, bone metabolism-related diseases

Yihui Ding, Dandan Wang, Chenlu Li, Jihong Wang, Lei Tian, Chunlin Zong. Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 297-306.

References

[1] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[2] 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4):313-325.
[3] Ruan HJ, Chen H, Hou JS, et al.Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw[J]. J Bone Oncol, 2024, 12(49):100650.
[4] 中华口腔医学会. 接受双膦酸盐治疗患者拔牙围手术期处理专家共识: T/CHSA081-2024[S]. 北京: 中国质量标准出版传媒有限公司; 中国标准出版社, 2024:32-43.
[5] Beth-Tasdogan NH, Mayer B, Hussein H, et al. Interventions for managing medication-related osteonecrosis of the jaw[J]. Cochrane Database Syst Rev, 2022, 07(12):CD012432.
[6] On SW, Cho SW, Byun SH, et al.Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches[J]. Antioxidants (Basel), 2021, 10(5):680.
[7] Abdolrahmani A, Epstein JB, Samim F.Medication-related osteonecrosis of the jaw: Evolving research for multimodality medical management[J]. Supportive Care Cancer, 2024, 32(4):212.
[8] Sim IW, Borromeo GL, Tsao C, et al.Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: A placebo-controlled, randomized trial[J]. J Clin Oncol, 2020, 38(26):2971-2980.
[9] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1157.
[10] Kyrgidis A, Toulis KA.Denosumab-related osteonecrosis of the jaws[J]. Osteoporos Int, 2011, 22(1): 369-370.
[11] Greuter S, Schmid F, Ruhstaller T, et al.Bevacizumab-associated osteonecrosis of the jaw[J]. Ann Oncol, 2008, 19(12):2091-2092.
[12] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication related osteonecrosis of the jaws-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10):1938-1956.
[13] Chen YJ, Wang SP, Cheng FC, et al.Intermittent parathyroid hormone improve bone microarchitecture of the mandible and femoral head in ovariectomized rats[J]. BMC Musculoskelet Disord, 2017, 18(1):171.
[14] Li JY, Yu M, Tyagi AM, et al.IL-17 Receptor Signaling in Osteoblasts/Oseocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production[J]. J Bone Mineral Res, 2019, 34(2):349-360.
[15] Chen T, Wang Y, Hao Z, et al.Parathyroid hormone and its related peptides in bone metabolism[J]. Biochem Pharmacol, 2021, 192:114669.
[16] Casado E, Martínez-Díaz-Guerra G, Caeiro JR. PTH/PTHrP analogues as osteoanabolic treatment in patients with osteoporosis[J]. Med Clin (Barc), 2025, 165(4):107076. English, Spanish.
[17] Harper RP, Fung E.Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone rhPTH(1-34)[J]. J Oral Maxillofac Surg, 2007, 65(3):573-580.
[18] Morishita K, Yamada SI, Kawakita A, et al.Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan[J]. J Orthop Sci, 2020, 25(6):1079-1083.
[19] Dos Santos Ferreira L, Abreu LG, Calderipe CB, et al. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis[J]. Osteoporos Int, 2021, 32(12):2449-2459.
[20] Singh A, Chung K, Huryn JM, et al.Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2025, 140(3):e59-e63.
[21] Kim RY, Hong SO, Jung JW, et al.Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: A report of two cases[J]. J Korean Assoc Oral Maxillofac Surg, 2024, 50(5):285-291.
[22] Choi SY, Yoon D, Kim KM, et al.Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: A report of three cases[J]. J Korean Assoc Oral Maxillofac Surg, 2024, 50(2):103-109.
[23] Mohamed MM, Gunasekera WM, Glew D, et al.Teriparatide therapy for medication-related osteonecrosis of the jaw: Case report and literature review[J]. Clin Med (Lond), 2022, 22(Suppl 4):20-21.
[24] Ohbayashi Y, Iwasaki A, Nakai F, et al.A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration[J]. Osteoporos Int, 2020, 31(3):577-585. Erratum in: Osteoporos Int, 2025, 36(1):159-160.
[25] Kim KM, Kim S, Hwang H, et al.Effects of daily versus weekly teriparatide for medication-related osteonecrosis of the jaw: A case-control study[J]. Oral Dis, 2024, 30(5):3286-3295.
[26] Yoshiga D, Yoshioka I, Habu M, et al.Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: A clinical case series[J]. Br J Oral Maxillofac Surg, 2022, 60(5):604-609.
[27] Jung J, Yoo HY, Kim GT, et al.Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study[J]. J Bone Miner Res, 2017, 32(12):2445-2452.
[28] Bassan Marinho Maciel G, Marinho Maciel R, Linhares Ferrazzo K, et al. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review[J]. J Mol Med (Berl), 2024, 102(3):353-364.
[29] Radović K, Brković B, Roganović J, et al.Salivary VEGF and Post-Extraction Wound Healing in Type 2 Diabetic Immediate Denture Wearers[J]. Acta Odontol Scand, 2022, 80(1):9-14.
[30] Vallina C, Ramírez L, Torres J, et al.Osteonecrosis of the jaws produced by sunitinib: a systematic review[J]. Med Oral Patol Oral Cir Bucal, 2019, 24(3):e326-e338.
[31] Badel T, Pavicin IS, Carek AJ, et al.Pathophysiology of osteonecrosis of the jaw in patients treated with bisphosphonate[J]. Coll Antropol, 2013, 37(2):645-651.
[32] Zandi M, Dehghan A, Mohammadi-Mofrad A, et al.Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats[J]. J Craniomaxillofac Surg, 2017, 45(2):275-280.
[33] Jung J, Shim GJ, Kim M, et al.Effect and timing of parathyroid hormone analog administration for preventing medication-related osteonecrosis of the jaws in a murine model[J]. J Craniomaxillofac Surg, 2021, 49(8):719-725.
[34] Keskinruzgar A, Bozdag Z, Aras MH, et al.Histopathological Effects of Teriparatide in Medication-Related Osteonecrosis of the Jaw: An Animal Study[J]. J Oral Maxillofac Surg, 2016, 74(1):68-78.
[35] Liu J, Mattheos N, Deng C, et al.Management of medication-related osteonecrosis of jaw: Comparison between icariin and teriparatide in a rat model[J]. J Periodontol, 2021, 92(1):149-158.
[36] Nakanishi-Kimura A, Takakura A, Hoshi-Numahata M, et al.Dynamic morphometric changes in the mandibular osteocytic lacunae of ovariectomized rats in response to teriparatide, as revealed by three-dimensional fluorescence analyses: Possible involvement of osteocytic perilacunar remodeling[J]. J Oral Biosci, 2024, 66(1): 49-60.
[37] Hasegawa T, Hayashida S, Kondo E, et al; Japanese Study Group of Co-operative Dentistry with Medicine (JCDM). Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study[J]. Osteoporos Int, 2019, 30(1):231-239.
[38] Moreno-Rabié C, Lapauw L, Gaêta-Araujo H, et al.Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction[J]. Sci Rep, 2022, 12(1):11280.
[39] Schwech N, Nilsson J, Gabre P.Incidence and risk factors for medication-related osteonecrosis after tooth extraction in cancer patients-A systematic review[J]. Clin Exp Dent Res, 2023, 9(1):55-65.
[40] Kwoen MJ, Park JH, Kim KS, et al.Association Between Periodontal Disease, Tooth Extraction, and Medication-Related Osteonecrosis of the Jaw in Women Receiving Bisphosphonates: A National Cohort-Based Study[J]. J Periodontol, 2023, 94(1):98-107.
[41] Li Q, Pu Y, Lu H, et al.Porphyromonas, Treponema, and Mogibacterium promote IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related osteonecrosis of the jaw[J]. J Oral Microbiol, 2020, 13(1):1851112.
[42] Wu S, Li F, Tan J, et al.Porphyromonas gingivalis induces bisphosphonate-related osteonecrosis of the Femur in mice[J]. Front Cell Infect Microbiol, 2022, 12: 886411.
[43] López-Jornet P, Camacho-Alonso F, Martínez-Canovas A, et al.Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws[J]. J Oral Maxillofac Surg, 2011, 69(10):2488-2493.
[44] Abtahi J, Agholme F, Aspenberg P.Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model[J]. Int J Oral Maxillofac Surg, 2013, 42(5):632-636.
[45] Zheng Y, Dong X, Chen S, et al.Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing[J]. BMC Oral Health, 2023, 23(1):14.
[46] Troeltzsch M, Zeiter S, Arens D, et al.Chronic Periodontal Infection and Not Iatrogenic Interference Is the Trigger of Medication-Related Osteonecrosis of the Jaw: Insights from a Large Animal Study (PerioBRONJ Pig Model)[J]. Medicina (Kaunas), 2023, 59(5):1000.
[47] Udeabor SE, Heselich A, Al-Maawi S, et al.Current Knowledge on the Healing of the Extraction Socket: A Narrative Review[J]. Bioengineering (Basel), 2023, 10(10):1145.
[48] Hayano H, Kuroshima S, Sasaki M, et al.Distinct immunopathology in the early stages between different antiresorptives related osteonecrosis of the jaw-like lesions in mice[J]. Bone, 2020, 135:115308.
[49] Jiang A, Zhang Z, Qiu X, et al.Medication-related osteonecrosis of the jaw (MRONJ): A review of pathogenesis hypothesis and therapy strategies[J]. Arch Toxicol, 2024, 98(3):689-708.
[50] Kuroshima S, Al-Omari FA, Sasaki M, et al.Medication-related osteonecrosis of the jaw: A literature review and update[J]. Genesis, 2022, 60(8-9):e23500.
[51] Kaur K, Kanayama K, Wu QQ, et al.Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2(-/-) mice stark differences between the bone marrow and gingivae[J]. Cell Immunol, 2022, 375:104526.
[52] Yang G, Collins JM, Rafiee R, et al.SIRT1 gene SNP rs932658 is associated with medication-related osteonecrosis of the jaw[J]. J Bone Miner Res, 2021, 36(2):347-356.
[53] Kim S, Mun S, Shin W, et al.Identification of potentially pathogenic variants associated with recurrence in medication-related osteonecrosis of the jaw (MRONJ) patients using whole-exome sequencing[J]. J Clin Med, 2022, 11(8):2145.

Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	Jinyuan He, Guowen Sun. Research Progress on the Mechanism and Treatment of Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 307-311.
[2]	Bingyue Xu, Han Lu, Keying Liu, Wei He. Advances in the Study of Microecological Dysbiosis in Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 312-321.
[3]	Yiyun Zhang, Feiwu Kang, Xueming Zhang. Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 322-330.
[4]	Chenxi Jiang, Guowen Sun. Research Progress in Clinical Diagnosis and Treatment of Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 331-336.
[5]	Rui Wang, Guowen Sun. A Retrospective Study of Surgical Treatment of Stage 3 Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 345-352.
[6]	Jinyuan He, Guowen Sun. One Case of the Guide Plate to Improve the Occlusal Relationship of Mandibular Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 360-366.
[7]	Na Li, Yuan Chang, Ning Gao, Kun Fu, Jinghua Cai, Zhenjie GAO, Xianghe Qiao, Leilei Yang, Wei He. Clinical Application of “Internet+”Case Teaching Method in Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 367-374.
[8]	Dong Shi, Chenhao Yu, Yan Si, Zhongchen Song, Xiangying Ouyang, Yi Liu, Wenjie Hu, Yaping Pan. Current Status and Future Strategies of Periodontal Health Management in China [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(4): 189-193.